Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Margaret Tempero, MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1600 Divisadero St.,MZ Bldg B
    San Francisco CA 94143
    Phone415-885-3846

       Biography 
       Education and Training
      Institution Degree School or Department Year
      University of NebraskaM.D.School of Medicine1977

       ORNG Applications 
       Websites
       In The News
       NIH Grants Awarded
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Tempero M. Cancer screening: when is the juice worth the squeeze? J Natl Compr Canc Netw. 2014 Oct; 12(10):1359.
        View in: PubMed
      2. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Sep 9.
        View in: PubMed
      3. Tempero M. Getting what you pay for: finding value in cancer care. J Natl Compr Canc Netw. 2014 Sep; 12(9):1199.
        View in: PubMed
      4. Tempero M. Incentive-based oncology: unintended consequences? J Natl Compr Canc Netw. 2014 Aug; 12(8):1069.
        View in: PubMed
      5. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93.
        View in: PubMed
      6. Tempero M. A publicly funded clinical trials network: do we need it? J Natl Compr Canc Netw. 2014 Jul; 12(7):953.
        View in: PubMed
      7. Tempero M. Embracing team-based oncology care. J Natl Compr Canc Netw. 2014 Jun; 12(6):845.
        View in: PubMed
      8. Tempero M. Managing the fruits of our success. J Natl Compr Canc Netw. 2014 May 1; 12(5):603.
        View in: PubMed
      9. Tempero M. The changing face of community practice: the new normal. J Natl Compr Canc Netw. 2014 Apr 1; 12(4):449.
        View in: PubMed
      10. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?: A Pooled Analysis of Phase II Trials of Gemcitabine-Containing Doublets Plus Bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
        View in: PubMed
      11. Tempero M. JNCCN Going Forward. J Natl Compr Canc Netw. 2014 Mar 1; 12(3):301.
        View in: PubMed
      12. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34.
        View in: PubMed
      13. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5.
        View in: PubMed
      14. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013 Jun; 144(6):1316-26.
        View in: PubMed
      15. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10; 31(17):2189-204.
        View in: PubMed
      16. Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res. 2013 Feb 1; 19(3):538-40.
        View in: PubMed
      17. Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):653-64.
        View in: PubMed
      18. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15; 491(7424):399-405.
        View in: PubMed
      19. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7.
        View in: PubMed
      20. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81.
        View in: PubMed
      21. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 1; 10(6):703-13.
        View in: PubMed
      22. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3.
        View in: PubMed
      23. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011 Jul; 22(7):1500-6.
        View in: PubMed
      24. Collisson E, Tempero M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res. 2011 Jan 15; 17(2):203-5.
        View in: PubMed
      25. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010 Sep; 8(9):972-1017.
        View in: PubMed
      26. International network of cancer genome projects. Nature. 2010 Apr 15; 464(7291):993-8.
        View in: PubMed
      27. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.
        View in: PubMed
      28. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.
        View in: PubMed
      29. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20; 27(33):5660-9.
        View in: PubMed
      30. Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5.
        View in: PubMed
      31. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74.
        View in: PubMed
      32. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol. 2008 Jun; 19 Suppl 6:vi1-8.
        View in: PubMed
      33. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71.
        View in: PubMed
      34. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52.
        View in: PubMed
      35. Tempero MA. How I treat pancreatic ductal adenocarcinoma. J Oncol Pract. 2008 Jan; 4(1):46-7.
        View in: PubMed
      36. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Nov; 5(10):998-1033.
        View in: PubMed
      37. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007 Jun; 18 Suppl 7:vii1-vii10.
        View in: PubMed
      38. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 1; 68(3):809-16.
        View in: PubMed
      39. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33.
        View in: PubMed
      40. Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007 Feb; 25(1):85-94.
        View in: PubMed
      41. Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res. 2006 Jan 1; 66(1):14-7.
        View in: PubMed
      42. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85.
        View in: PubMed
      43. Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53.
        View in: PubMed
      44. Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):598-626.
        View in: PubMed
      45. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36.
        View in: PubMed
      46. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9.
        View in: PubMed
      47. Tempero MA. Clinical oncology 2004: the president's report. J Clin Oncol. 2004 Nov 15; 22(22):4437-41.
        View in: PubMed
      48. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003 Sep 15; 21(18):3402-8.
        View in: PubMed
      49. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34(2-3):107-16.
        View in: PubMed
      50. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002 Sep; 2(8):774-9.
        View in: PubMed
      51. Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med. 2002 Jul; 43(7):957-67.
        View in: PubMed
      52. Ko AH, Tempero MA. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12.
        View in: PubMed
      53. Augustine SC, Norenberg JP, Colcher DM, Vose JM, Gobar LS, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero MA. Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc (Wash). 2002 Jan-Feb; 42(1):93-100.
        View in: PubMed
      54. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001 Jun 15; 61(12):4923-32.
        View in: PubMed
      55. Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, Dukat VJ, Hohenstein MA, Gobar LS, Vose JM. Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001 Jun; 42(6):907-15.
        View in: PubMed
      56. Copur MS, Capadano M, Lynch J, Goertzen T, McCowan T, Brand R, Tempero M. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. J Clin Oncol. 2001 May 1; 19(9):2404-12.
        View in: PubMed
      57. Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Booth BJ, Pavlinkova G, Tempero M, Batra SK. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs. Clin Cancer Res. 2001 Jan; 7(1):175-84.
        View in: PubMed
      58. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000 Aug; 6(8):3095-102.
        View in: PubMed
      59. Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, Leichner P, Lynch JC, Goldenberg D, Armitage JO. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma. 2000 Jun; 38(1-2):91-101.
        View in: PubMed
      60. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000 Feb; 6(2):406-14.
        View in: PubMed
      61. Gwilt P, Tempero M, Kremer A, Connolly M, Ding C. Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil. Cancer Chemother Pharmacol. 2000; 45(3):247-51.
        View in: PubMed
      62. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999 Dec; 117(6):1464-84.
        View in: PubMed
      63. Brand RE, Tempero MA. Pancreatic cancer. Curr Opin Oncol. 1998 Jul; 10(4):362-6.
        View in: PubMed
      64. Tempero MA, Brand R. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1998 May 1; 82(9):1800-1.
        View in: PubMed
      65. Habbe TG, McCowan TC, Goertzen TC, Leveen RF, Culp WC, Tempero MA. Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy. J Vasc Interv Radiol. 1998 Mar-Apr; 9(2):233-9.
        View in: PubMed
      66. Tempero M. Biologic therapy of gastrointestinal cancer. Cancer Treat Res. 1998; 98:227-37.
        View in: PubMed
      67. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997 Apr; 38(4):512-6.
        View in: PubMed
      68. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlam J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol. 1997 Apr; 15(4):1518-28.
        View in: PubMed
      69. Tempero MA. Walking a difficult path is easier with a friend. Thoughts from a practicing oncologist. Ann N Y Acad Sci. 1997 Feb 20; 809:237-42.
        View in: PubMed
      70. Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 1997; 15(4):331-41.
        View in: PubMed
      71. Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, Colcher D. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. J Clin Immunol. 1997 Jan; 17(1):96-106.
        View in: PubMed
      72. Engstrom PF, Benson AB, Cohen A, Doroshow J, Kiel K, Niederhuber J, Roh M, Tempero M. NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Nov; 10(11 Suppl):140-75.
        View in: PubMed
      73. Haga Y, Tempero MA, Zetterman RK. Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes. Biochim Biophys Acta. 1996 Oct 7; 1317(1):65-70.
        View in: PubMed
      74. Haga Y, Tempero MA, Kay D, Zetterman RK. Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutin-induced proliferation and interleukin-2 production of human lymphocytes. Dig Dis Sci. 1996 Jul; 41(7):1468-74.
        View in: PubMed
      75. Haga Y, Tempero MA, Zetterman RK. Unconjugated bilirubin inhibits in vitro major histocompatibility complex-unrestricted cytotoxicity of human lymphocytes. Biochim Biophys Acta. 1996 May 24; 1316(1):29-34.
        View in: PubMed
      76. Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK. Radiolabeled iododeoxyuridine: safety evaluation. J Nucl Med. 1996 Apr; 37(4 Suppl):13S-16S.
        View in: PubMed
      77. Tempero M, Brand R, Holdeman K, Matamoros A. New imaging techniques in colorectal cancer. Semin Oncol. 1995 Oct; 22(5):448-71.
        View in: PubMed
      78. Sivinski CL, Lindner DJ, Borden EC, Tempero MA. Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons. J Immunother Emphasis Tumor Immunol. 1995 Oct; 18(3):156-65.
        View in: PubMed
      79. Harrison KA, Tempero MA. Diagnostic use of radiolabeled antibodies for cancer. Oncology (Williston Park). 1995 Jul; 9(7):625-31 DISC 634, 636, 641.
        View in: PubMed
      80. Tan-Shalaby J, Tempero M. Malignancies after liver transplantation: a comparative review. Semin Liver Dis. 1995 May; 15(2):156-64.
        View in: PubMed
      81. Kessinger A, Bishop MR, Anderson JR, Armitage JO, Bierman PJ, Reed EC, Tarantolo S, Tempero MA, Vose JM, Warkentin PI. Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization. J Hematother. 1995 Apr; 4(2):81-4.
        View in: PubMed
      82. Tempero MA, Haga Y, Sivinski C, Birt D, Klassen L, Thiele G. Immunologic effects of levamisole in mice and humans: evidence for augmented antibody response without modulation of cellular cytotoxicity. J Immunother Emphasis Tumor Immunol. 1995 Jan; 17(1):47-57.
        View in: PubMed
      83. Kornbrot B, Kobayashi RH, Singer A, Tempero MA, Heiner DC. Hypersensitivity to therapeutic murine monoclonal antibodies. Nebr Med J. 1994 Dec; 79(12):393-8.
        View in: PubMed
      84. Tempero M, Anderson J. Progress in colon cancer: do molecular markers matter? N Engl J Med. 1994 Jul 28; 331(4):267-8.
        View in: PubMed
      85. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev. 1994 Mar; 3(2):155-60.
        View in: PubMed
      86. Haga Y, Sivinski CL, Woo D, Tempero MA. Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. Int J Pancreatol. 1994 Feb; 15(1):43-50.
        View in: PubMed
      87. Tempero M, Colcher D, Dalrymple G, Harrison K, Holdeman K, Joshi S, Quadri S, Linder J, Augustine S, Reed E, et al. Cancer therapy using radioimmunoconjugates. Implications for breast cancer. Ann N Y Acad Sci. 1993 Nov 30; 698:406-17.
        View in: PubMed
      88. Tempero M. Pitfalls in antibody imaging in colorectal cancer. Cancer. 1993 Jun 15; 71(12 Suppl):4248-51.
        View in: PubMed
      89. Hirota M, Pour PM, Tempero MA, Chaney WG. Purification and analysis of glycoproteins bearing blood group-A determinants from hamster pancreatic ductal adenocarcinomas. Carcinogenesis. 1992 Oct; 13(10):1829-33.
        View in: PubMed
      90. Haga Y, Kay HD, Tempero MA, Zetterman RK. Flow cytometric measurement of intracellular bilirubin in human peripheral blood mononuclear cells exposed to unconjugated bilirubin. Clin Biochem. 1992 Aug; 25(4):277-83.
        View in: PubMed
      91. Haga Y, Tempero MA, Kay HD, Zetterman RK. Characterization of bilirubin transport system by human peripheral blood mononuclear cells. J Leukoc Biol. 1992 Jan; 51(1):2-6.
        View in: PubMed
      92. Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, Quaife MA, Sharp JG. Quantitation of metastatic tumor burden from human colon tumor xenografts using radiolabelled monoclonal antibody 17-A fragments. Tumour Biol. 1992; 13(4):195-206.
        View in: PubMed
      93. Tempero MA. Progress in chemoprevention of gastrointestinal cancers. Curr Opin Oncol. 1991 Aug; 3(4):719-26.
        View in: PubMed
      94. Egami H, Tomioka T, Tempero M, Kay D, Pour PM. Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters. Am J Pathol. 1991 Mar; 138(3):557-61.
        View in: PubMed
      95. Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, Pour P. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma. Int J Pancreatol. 1991; 9:125-34.
        View in: PubMed
      96. Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J Clin Oncol. 1990 Dec; 8(12):2019-26.
        View in: PubMed
      97. Tempero MA. Advances in the medical management of advanced gastrointestinal cancers. Curr Opin Oncol. 1990 Aug; 2(4):747-53.
        View in: PubMed
      98. Tempero MA, Nishioka K, Knott K, Zetterman RK. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res. 1989 Nov 1; 49(21):5793-7.
        View in: PubMed
      99. Takiyama Y, Tempero MA, Takasaki H, Onda M, Tsuchiya R, Büchler M, Ness M, Colcher D, Schlom J, Pour PM. Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases. Hum Pathol. 1989 Sep; 20(9):832-8.
        View in: PubMed
      100. Wettendorff M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A. Proc Natl Acad Sci U S A. 1989 May; 86(10):3787-91.
        View in: PubMed
      101. Tempero M, Takasaki H, Uchida E, Takiyama Y, Colcher D, Metzgar RS, Pour PM. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma. Am J Surg Pathol. 1989; 13 Suppl 1:89-95.
        View in: PubMed
      102. Takasaki H, Tempero MA, Uchida E, Büchler M, Ness MJ, Burnett DA, Metzgar RS, Colcher D, Schlom J, Pour PM. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. Int J Cancer. 1988 Nov 15; 42(5):681-6.
        View in: PubMed
      103. Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA, Steplewski Z. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res. 1988 Oct 1; 48(19):5422-6.
        View in: PubMed
      104. Ness MJ, Pour PM, Tempero MA, Linder J. Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. Mod Pathol. 1988 Jul; 1(4):279-83.
        View in: PubMed
      105. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 1988 Mar 15; 48(6):1435-8.
        View in: PubMed
      106. Tempero MA, Knott KK, Zetterman RK. Relationship of dietary cholesterol and cellulose in the prevention of colon cancer. Cancer Detect Prev. 1988; 13(1):41-54.
        View in: PubMed
      107. Tempero MA, Zetterman RK. Effects of sodium cholate on experimental carcinogenesis and cell proliferation in an excluded colonic segment. J Surg Oncol. 1987 Dec; 36(4):253-8.
        View in: PubMed
      108. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987 Oct 15; 47(20):5501-3.
        View in: PubMed
      109. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue. Int J Pancreatol. 1987 Oct-Dec; 2(5-6):349-60.
        View in: PubMed
      110. Uchida E, Tempero MA, Burnett DA, Steplewski Z, Pour PM. Correlative studies on antigenicity of pancreatic cancer and blood group types. Cancer Detect Prev Suppl. 1987; 1:145-8.
        View in: PubMed
      111. Petrie HT, Klassen LW, Tempero MA, Kay HD. In vitro regulation of human lymphocyte proliferation by selenium. Biol Trace Elem Res. 1986 Dec; 11(1):129-46.
        View in: PubMed
      112. Tempero MA, Deschner EE, Zedeck MS. The effect of selenium on cell proliferation in liver and colon. Biol Trace Elem Res. 1986 Aug; 10(2):145-52.
        View in: PubMed
      113. Herlyn D, Sears H, Iliopoulos D, Lubeck M, Douillard JY, Sindelar W, Tempero M, Mellstedt H, Maher M, Koprowski H. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma. 1986 Jul; 5 Suppl 1:S51-8.
        View in: PubMed
      114. Tempero MA, Williams CA, Anderson JC. The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. J Clin Oncol. 1986 Jul; 4(7):1074-8.
        View in: PubMed
      115. Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma. 1986 Jul; 5 Suppl 1:S133-8.
        View in: PubMed
      116. Thompson JS, Tempero MA, Haun JL, Vanderhoof JA. The importance of luminal factors in neomucosal growth. J Surg Res. 1986 Feb; 40(2):126-32.
        View in: PubMed
      117. Tempero M. Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review. Dig Dis. 1986; 4(1):49-56.
        View in: PubMed
      118. Berg AR, Linder J, Anderson RW, Tempero MA, Edney JA, Armitage JO. The undifferentiated malignant neoplasm. Identification of lymphoma arising in skeletal muscle by immunohistochemical analysis. JAMA. 1985 Nov 8; 254(18):2625-6.
        View in: PubMed
      119. Tempero MA, Davis RB, Reed E, Edney J. Thrombocytopenia and laboratory evidence of disseminated intravascular coagulation after shunts for ascites in malignant disease. Cancer. 1985 Jun 1; 55(11):2718-21.
        View in: PubMed
      120. Tempero MA, Jacobs MM, Lynch HT, Graham CL, Blotcky AJ. Serum and hair selenium levels in hereditary nonpolyposis colorectal cancer. Biol Trace Elem Res. 1984 Feb; 6(1):51-5.
        View in: PubMed
      121. Tempero MA, Kessinger A. Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma. J Surg Oncol. 1982 Nov; 21(3):159-61.
        View in: PubMed
      122. Tempero MA, Petersen RJ, Zetterman RK, Lemon HM, Gurney J. Detection of metastatic liver disease. Use of liver scans and biochemical liver tests. JAMA. 1982 Sep 17; 248(11):1329-32.
        View in: PubMed
      123. Tempero M, Kessinger A, Lemon HM. VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy. Cancer Clin Trials. 1981; 4(2):155-7.
        View in: PubMed
      124. Tempero MA, Smith PW. Disseminated Mycobacterium kansasii presenting with skin lesions in a patient with chronic lymphocytic leukemia. Med Pediatr Oncol. 1981; 9(3):283-8.
        View in: PubMed
      Margaret's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP